According to a literature survey, the Incidence of CIHL was estimated to be 50-60% of children treated with cisplatin, and 5-20% of those treated with carboplatin acquire some degree of irreversible hearing loss. The incidence increases to 80% – 90% in those receiving cisplatin and myeloablative carboplatin. According to Thelansis Research, the reported incidence of CIHL ranges between 18– 98%, depending upon age, sex, degree of exposure, and comorbid condition.
Comprehensive insight on patient segmentation based on age, sex, Tumor types and sites (Lung, Head/neck & Brain, Kidney /bladder, Uterus / Ovarian), Cisplatin cumulative dose, and comorbidities (Hypertension and Diabetes), Chemotherapy agent-specific frequency of CHIL, severity, and grades (0,1a-1b,2a-2b,3,4), of CIHL, Signs & Symptoms, Clinical Manifestations (bilateral, symmetrical, sensorineural hearing loss with or without tinnitus and vertigo), Treatment types has been provided into the epidemiology section of the CISPLATIN INDUCED HEARING LOSS (CIHL) and its treatment in the 8 MM countries, covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China
DB-020 is an investigational therapy for the prevention of cisplatin-induced hearing loss. Decibel completed a randomized, double-blind, placebo-controlled Phase 1 clinical trial of DB-020 in healthy volunteers, in which DB-020 was well tolerated. An ongoing, Phase 1b randomized, double-blind, placebo-controlled, multicenter clinical trial is assessing safety and efficacy in patients receiving cisplatin chemotherapy. DB-020 comprises a proprietary formulation of sodium thiosulfate, or STS, which has been optimized for delivery to the ear. By locally disabling cisplatin in the cochlea. OTO-104 assets from Otonomy Inc. terminated in 2nd stage of their critical trial due to lack of satisfactory study outcomes.
Thelansis is specialized in pharmaceutical market research and market Insight Report Company, published reports across the therapeutic area which includes both rare / ultra-rare and mainstream indication. Over the period of time, we have built a strong repository of 6,000+ Bio-pharma reports which essentially covers Epidemiology study and Market forecasting based on the KOL opinions. Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the major focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.
Gurugram- Onework Gold Souk mall, Phase I, Sector 43, Haryana-122002, India
Contact no.: +91(124) 404-1731
183-Asylum Street Hartford, CT-06103, USA
USA +1 (267) 244-6955,